000			02919nam a22003857a 4500
008			210607s20212021 xxu||||| |||| 00| 0 eng d
022			_a1177-5467
024			_a10.2147/OPTH.S259012 [doi]
024			_a259012 [pii]
024			_aPMC8018415 [pmc]
040			_aOvid MEDLINE(R)
099			_a33824576
245			_aOutcomes of Conductive Keratoplasty Combined with Corneal Crosslinking in Advanced Ectatic Corneal Disease.
251			_aClinical Ophthalmology. 15:1317-1329, 2021.
252			_aClin. ophthalmol.. 15:1317-1329, 2021.
253			_aClinical ophthalmology (Auckland, N.Z.)
260			_c2021
260			_fFY2021
265			_sepublish
266			_d2021-06-07
520			_aConclusion: Conductive keratoplasty with a proprietary epi-on CXL treatment improved vision in patients with advanced ectasia This CK/epi-on CXL treatment offers the possibility of improved VA for patients with compromised vision due to ectasia. Copyright (c) 2021 Sinjab et al.
520			_aMethods: Retrospective, exploratory cohort study. Patients with keratoconus or postsurgical ectasia and best spectacle-corrected distance VA (CDVA) <= 20/40 were included. Conductive keratoplasty was performed (ViewPoint CK System, Refractec, Inc., Bloomington, MN); followed a day later by epi-on CXL (CXLUSA/CXLO, Bethesda, MD/CXLO Encinitas, CA). Measures included uncorrected distance visual acuity (UDVA) and CDVA, as well as refractive and tomographic measures and tomographic indices.
520			_aPurpose: To assess the effectiveness of a novel treatment for patients with advanced corneal ectasia and loss of visual acuity (VA). Conductive keratoplasty (CK) is performed to improve VA followed by epithelium-on (epi-on) corneal crosslinking (CXL) to stabilize the cornea after CK.
520			_aResults: Data from 50 eyes of 45 patients were analyzed. Mean follow-up was 15.1 +/- 12.2 months (range: 2 to 51). Overall, UDVA and CDVA improved postoperatively. Subjective refraction and tomographic metrics did not show consistent changes, but changes in tomographic indices were associated with treatment follow-up time. At the 1-year visit, mean UDVA significantly improved over baseline (P = 0.009) by approximately 3 lines; mean CDVA improved significantly (P = 10-5) by approximately 2 lines. No eye lost lines of CDVA. Change in the Index of Surface Variance (ISV) was associated with treatment, and the D-Index trended over follow-up time.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aOphthalmology
657			_aJournal Article
700			_aRubinfeld, Roy S
700			_aWagner, Kirsten
790			_aBelin MW, Cummings AB, Parsons Jnr EC, Rubinfeld RS, Sinjab MM, Wagner K
856			_uhttps://dx.doi.org/10.2147/OPTH.S259012 _zhttps://dx.doi.org/10.2147/OPTH.S259012
942			_cART _dArticle
999			_c6396 _d6396